Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

Post by: Diane De wyngaert in Press Release Tubulis
TUB-040 is a next-generation NaPi2b-targeting…
read more
21 Jun 2024
0

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Post by: Diane De wyngaert in Press Release Tubulis
Financing round co-led by EQT…
read more
14 Mar 2024
0

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Post by: Diane De wyngaert in Press Release Tubulis
Companies join forces bringing together…
read more
20 Apr 2023
0

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Post by: Diane De wyngaert in Press Release Tubulis
Tubulis Closes €60 Million Series…
read more
03 May 2022
0